travoprost · Novartis · NDA 204822
Izba
Earliest generic entry, as listed
10 Oct 2029
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8178582, US 8722735.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8178582 | drug product · sets the listed date | 10 Oct 2029 |
| US 8722735 | drug product · sets the listed date | 10 Oct 2029 |
| US 8754123 | drug product | 19 May 2029 |
| US 9144561 | drug product | 13 Mar 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 204822 · 001 · RLD · discontinued | solution/drops, ophthalmic | 0.003% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 10 Oct 2029 |